Exosome Diagnostics, the developer of the leading liquid biopsy platform that enables non-invasive diagnosis of disease states, aiming to obviate the need for tissue biopsies, has announced its "Academic Bench to Clinical Diagnostics" (A to D) Assay Commercialization Program.